source
- Abbott reports 30‑day success in Tectonic trial of SonicForce coronary IVL systemAbbott announced that its investigational SonicForce Coronary IVL system achieved positive 30‑day outcomes in the Tectonic trial involving patients with severely calcified coronary artery disease.…
- AbbVie halts development of livmoniplimab after deeming benefit limitedAbbVie announced it is discontinuing the phase 2 development of its monoclonal antibody livmoniplimab (ABBV-151) after concluding the drug is unlikely to outperform existing therapies. The drug wa…